---
title: Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia
nct_id: NCT04563104
overall_status: COMPLETED
sponsor: Ain Shams University
study_type: OBSERVATIONAL
primary_condition: Ventilator Associated Pneumonia
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04563104.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04563104"
ct_last_update_post_date: 2021-09-28
last_seen_at: "2026-05-12T07:28:55.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia

**NCT ID:** [NCT04563104](https://clinicaltrials.gov/study/NCT04563104)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 62
- **Lead Sponsor:** Ain Shams University
- **Conditions:** Ventilator Associated Pneumonia
- **Start Date:** 2020-10-01
- **Completion Date:** 2021-09-01
- **CT.gov Last Update:** 2021-09-28

## Brief Summary

Ventilator Associated pneumonia (VAP) is associated with longer ICU length of stay, prolonged mechanical ventilation, and increased use of antimicrobials, health-care cost and mortality . Acute respiratory infections (ARIs) comprise a large and heterogeneous group of infections, including bacterial infections, viral infections, and infections of other etiologies. Early initiation of adequate antibiotic therapy is the cornerstone in the treatment. However, overuse of antibiotics and prolonged duration of antibiotic therapy in patients with bacterial ARIs in the hospital and intensive care setting is associated with increased resistance for common bacteria, high costs, and adverse drug reactions.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years old or greater
* Ventilator associated pneumonia (VAP) with positive sputum culture.

Exclusion Criteria:

* pregnancy,
* use of immunosuppressive agents except for steroids,
* neutropenia (white blood cell count ≤1000/mL)
* patients whose primary diagnosis was community acquired pneumonia and other source of infection.
```

## Interventions

- **Lung Ultrasound** (DIAGNOSTIC_TEST) — We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.

## Primary Outcomes

- **correlation between lung ultrasound and procalcitonin.** _(time frame: 7 days)_

## Locations (1)

- Ain Shams University, Cairo, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ain shams university|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04563104.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04563104*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*